<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053493</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00050042</org_study_id>
    <nct_id>NCT02053493</nct_id>
  </id_info>
  <brief_title>Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: NIH Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blinded, placebo-controlled crossover study to assess effect of
      isosorbide mononitrate with dose up-titration on activity tolerance as assessed by
      (hip-worn, tri-axial) accelerometry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day
      averaged arbitrary accelerometry units in comparison to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in arbitrary accelerometry units</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. Participants will be assessed at weeks 5-6 and weeks 11-12 Comparison of weeks 5/6 and weeks 11/12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk distance</measure>
    <time_frame>Baseline, week 7 , week 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity and quality of life by 6 minute walk distance in comparison to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in  daily activity</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by additional accelerometry endpoints:
Hours active per day during maximal dose of study drug
Slope of daily averaged arbitrary accelerometry units during study drug administration
Area under the curve of daily averaged arbitrary accelerometry units during study drug administration
Participants will be assessed: Hours of activity at weeks 5-6 and 11-12; Slope comparison at weeks 3-6 and 9-12; AUC comparison of weeks 3-6 and 9-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference for isosorbide mononitrate treatment at the end of study.</measure>
    <time_frame>30 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self reported participant preference for study period 1 vs. study period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg Score during 6 minute walk test</measure>
    <time_frame>Baseline, week 7 and week 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate improves functional capacity and quality of life in comparison to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score(Kansas City Cardiomyopathy Questionnaire)</measure>
    <time_frame>Baseline, week 7 and week 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate improves functional capacity and quality of life in comparison to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro-B-type natriuretic peptide level</measure>
    <time_frame>Baseline, week 7 and week 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <condition>Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide Mononitate Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate</intervention_name>
    <description>Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks  5 and 6: 120 mg ISMN
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN</description>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
    <other_name>Imdur, ISMO, Monoket</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks  5 and 6: 120 mg Placebo
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo</description>
    <arm_group_label>Isosorbide Mononitate Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 50 years

          2. Symptoms of dyspnea (NYHA class II-IV) without evidence of a non-cardiac or ischemic
             explanation for dyspnea

          3. Ejection fraction (EF) ≥ 50% as determined on imaging study within 12 months of
             enrollment with no change in clinical status suggesting potential for deterioration
             in systolic function

          4. Stable medical therapy for 30 days as defined by:

               -  No addition or removal of ACE, Angiotensin receptor blockers (ARBs),
                  beta-blockers, calcium channel blockers  (CCBs) or aldosterone antagonists

               -  No change in dosage of ACE, ARBs, beta-blockers,CCBs or aldosterone antagonists
                  of more than 100%

          5. One of the following within the last 12 months

               -  Previous hospitalization for heart failure (HF) with radiographic evidence of
                  pulmonary congestion (pulmonary venous hypertension, vascular congestion,
                  interstitial edema, pleural effusion) or

               -  Catheterization documented elevated filling pressures at rest (LVEDP≥15 or
                  PCWP≥20) or with exercise (PCWP≥25) or

               -  Elevated NT-proBNP (&gt; 400 pg/ml) or BNP (&gt; 200 pg/ml) or

               -  Echo evidence of diastolic dysfunction / elevated filling pressures (at least
                  two) E/A &gt; 1.5  + decrease in E/A of &gt; 0.5 with valsalva Deceleration time ≤ 140
                  ms Pulmonary vein velocity in systole &lt; diastole (PVs&lt;PVd)sinus rhythm) E/e'≥15
                  Left atrial enlargement (≥ moderate) Pulmonary artery systolic pressure &gt; 40
                  mmHg Evidence of left ventricular hypertrophy

               -  LV mass/BSA ≥ 96 (♀) or ≥ 116 (♂) g/m2

               -  Relative wall thickness ≥ 0.43 (♂ or ♀) [(IVS+PW)/LVEDD]

               -  Posterior wall thickness ≥ 0.9 (♀) or 1.0 (♂) cm

          6. No chronic nitrate therapy or infrequent (≤ 1x week) use of intermittent sublingual
             nitroglycerin within last 3 months

          7. Ambulatory (not wheelchair / scooter / walker / cane dependent)

          8. HF is the primary factor limiting activity as indicated by answering # 2 to the
             following question:

        My ability to be active is most limited by:

          1. Joint, foot, leg, hip or back pain

          2. Shortness of breath and/or fatigue and/or chest pain

          3. Unsteadiness or dizziness

          4. Lifestyle, weather, or I just don't like to be active

        9. Body size allows wearing of the accelerometer belt as confirmed by ability to
        comfortably fasten the test belt provided for the screening process (belt designed to fit
        persons with  BMI 20-40 Kg/m2  but belt may fit some persons outside this range)

        10. Willingness to wear the accelerometer belt for the duration of the trial 11.
        Willingness to provide informed consent

        Exclusion Criteria:

          1. Recent (&lt; 3 months) hospitalization for HF

          2. Hemoglobin &lt; 8.0 g/dl

          3. Glomerular filtration rate &lt; 20 ml/min/1.73 m2 on most recent clinical laboratories

          4. SBP &lt; 110 mmHg or &gt; 180 mmHg at consent

          5. Diastolic blood pressure &lt; 40 mmHg or &gt; 100 mmHg at consent

          6. Resting HR &gt; 110 bpm at consent

          7. Previous adverse reaction to nitrates necessitating withdrawal of therapy

          8. Chronic therapy with phosphodiesterase type-5 inhibitors (intermittent use of
             phosphodiesterase type-5 inhibitors for erectile dysfunction is allowable if the
             patient is willing to hold for the duration of the trial)

          9. Regularly (&gt; 1x per week) swims or does water aerobics

         10. Significant COPD thought to contribute to dyspnea

         11. Ischemia thought to contribute to dyspnea

         12. Documentation of previous EF &lt; 50%

         13. Acute coronary syndrome within 3 months defined by electrocardiographic changes and
             biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting
             (chest discomfort or anginal equivalent)

         14. Percutaneous coronary intervention, coronary artery bypass grafting or new
             biventricular pacing within past 3 months

         15. Primary hypertrophic cardiomyopathy

         16. Infiltrative cardiomyopathy (amyloid)

         17. Constrictive pericarditis or tamponade

         18. Active myocarditis

         19. Complex congenital heart disease

         20. Active collagen vascular disease

         21. More than mild aortic or mitral stenosis

         22. Intrinsic (prolapse, rheumatic) valve disease with moderate to severe or severe
             mitral, tricuspid or aortic regurgitation

         23. Acute or chronic severe liver disease as evidenced by any of the following:
             encephalopathy, variceal bleeding, INR &gt; 1.7 in the absence of anticoagulation
             treatment

         24. Terminal illness (other than HF) with expected survival of less than 1 year

         25. Enrollment or planned enrollment in another therapeutic clinical trial in the next 3
             months

         26. Inability to comply with planned study procedures

         27. Pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Anstrom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Moore, RN, PMP</last_name>
    <phone>919-668-8065</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela DiSabatino</last_name>
      <phone>302-733-2658</phone>
    </contact>
    <investigator>
      <last_name>Mitchell Saltzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Snell</last_name>
      <phone>404-712-0531</phone>
    </contact>
    <investigator>
      <last_name>Javed Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hamorabi Mkrdichian</last_name>
      <phone>312-926-2773</phone>
    </contact>
    <investigator>
      <last_name>Sanjiv Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Bacher</last_name>
      <phone>410-502-3173</phone>
    </contact>
    <investigator>
      <last_name>Ryan Tedford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Brooks</last_name>
      <phone>617-732-6237</phone>
    </contact>
    <investigator>
      <last_name>Michael Givertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Cocca-Spofford</last_name>
      <phone>617-726-8228</phone>
    </contact>
    <investigator>
      <last_name>Marc Semigran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Jamieson</last_name>
      <phone>617-636-4435</phone>
    </contact>
    <investigator>
      <last_name>Gordon Huggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston V.A. Healthcare System</name>
      <address>
        <city>West Roxbury</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samantha Ly</last_name>
      <phone>857-203-6255</phone>
    </contact>
    <investigator>
      <last_name>Neal Lakdawala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Gatzke</last_name>
      <phone>507-538-7177</phone>
    </contact>
    <investigator>
      <last_name>Margaret Redfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janice Amsler</last_name>
      <phone>314-747-8542</phone>
    </contact>
    <investigator>
      <last_name>Susan Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Adams</last_name>
      <phone>919-668-8222</phone>
    </contact>
    <investigator>
      <last_name>Michael Felker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Durham V.A. Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Aristy</last_name>
      <phone>919-286-6941</phone>
    </contact>
    <investigator>
      <last_name>Mark Donahue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Fonk</last_name>
      <phone>216-445-1766</phone>
    </contact>
    <investigator>
      <last_name>Wilson Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Scheutzow</last_name>
      <phone>216-286-6550</phone>
    </contact>
    <investigator>
      <last_name>Oliveira Guilherme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Dettmer</last_name>
      <phone>216-778-2714</phone>
    </contact>
    <investigator>
      <last_name>Mark Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heidi Testa</last_name>
      <phone>717-544-1777</phone>
    </contact>
    <investigator>
      <last_name>Mark Etter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Gallagher</last_name>
      <phone>215-955-8184</phone>
    </contact>
    <investigator>
      <last_name>David Whellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marisa Konig</last_name>
      <phone>215-662-3236</phone>
      <email>konigmar@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Margulies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francine McGonagle</last_name>
      <phone>215-707-5839</phone>
    </contact>
    <investigator>
      <last_name>Rene Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michael E Debakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrienne Chee</last_name>
      <phone>713-791-1414</phone>
    </contact>
    <investigator>
      <last_name>Anita Deswal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Whipple</last_name>
      <phone>801-587-9048</phone>
    </contact>
    <investigator>
      <last_name>Jose Nativi-Nicolau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>V.A. Medical Center</name>
      <address>
        <city>Salt Lake CIty</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Whipple</last_name>
      <phone>801-587-9048</phone>
    </contact>
    <investigator>
      <last_name>Jose Nativi-Nicolau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont - Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Chadwick</last_name>
      <phone>802-847-4744</phone>
    </contact>
    <investigator>
      <last_name>Martin LeWinter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Preserved Ejection Fraction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
